Navigation Links
Pharmasset Presents Clevudine and Racivir Data at the International,HIV Drug Resistance Workshop

PRINCETON, N.J., June 14, 2007 /PRNewswire-FirstCall/ -- Pharmasset, Inc. , a clinical-stage pharmaceutical company committed to discovering, developing and commercializing novel drugs to treat viral infections, announced today that scientific data presentations about Clevudine and Racivir were made during the 16th International HIV Drug Resistance Workshop being held in St. Michael, Barbados from June 12-15, 2007. The poster presentations are available in the "Events & Presentations" section of Pharmasset's website at http://www.pharmasset.com.

An in vitro study of Clevudine, expected to enter Phase 3 registration clinical trials for the treatment of hepatitis B virus (HBV), demonstrated that it does not inhibit human immunodeficiency virus (HIV). Since Clevudine has demonstrated no antiviral effect on HIV, it should not select for HIV mutations that will have cross-resistance to HIV therapies. Thus, Clevudine may be useful for the treatment of HIV/HBV co-infected patients.

In addition, a clonal analysis of the Phase 2 viral samples for Racivir, being developed for the treatment of HIV, confirmed its antiviral activity in treatment-experienced patients with the M184V mutation and less than three thymidine analog mutations (TAMs). Thus, Racivir may be useful for the treatment of patients who have failed their first-line HIV therapy.

Anti-HIV Activity and Resistance Profiles of Entecavir Compared to Clevudine

Zennou V, Keilman M, Otto MJ, Furman P

Study Conclusion: Clevudine does not inhibit HIV in vitro. We have confirmed that entecavir has activity against wild type HIV-1 virus and that the M184V mutation confers resistance to entecavir. In addition, we showed that certain nucleoside-resistant HIV variants remain sensitive to entecavir. Thus, Clevudine may be useful for the treatment of HIV/HBV co-infected patients
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Pharmasset Announces Clevudine and Hepatitis C Presentations at EASL
2. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
3. European Society for Medical Oncology (ESMO) Presents Data from the Clinical Trial of MediGenes Cancer-Killing Virus in Press Conference
4. Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Quadramet at International Myeloma Workshop
5. SemBioSys Presents Positive Insulin Data at the American Diabetes Association Conference
6. Tranzyme Pharma Presents Initial Phase IIa Data for its Novel Ghrelin Agonist, TZP-101, in Patients with Diabetic Gastroparesis
7. Novagali Pharma Presents at AACO the Results of its Pivotal Phase III Clinical Trial of Vekacia in Children Suffering From Vernal Keratoconjunctivitis
8. BioLife Solutions Presents Data on CryoStor at International Society for Cellular Therapy Annual Meeting
9. Genaera Presents Preclinical Data on Trodusquemine (MSI-1436) for the Treatment of Obesity at the American Diabetes Association 67th Scientific Session
10. Elixir Pharmaceuticals Presents Preclinical Data Highlighting Its Ghrelin Antagonist Program at the American Diabetes Associations Annual Meeting
11. DiObex Presents Phase 2a Data of DIO-902 Demonstrating Trends of Improved Glycemic Control and Significant Reductions of LDL-Cholesterol and C-Reactive Protein
Post Your Comments:
(Date:12/19/2014)... has witnessed robust development with the growth pace keeping at ... In 2012, the size of China ... worldwide soaring to 16.3%. It is projected that ... rate by around 20% in the upcoming years and that ... An integrated membrane industrial system has taken shape ...
(Date:12/17/2014)... , Dec. 17, 2014  Strategic Health Services, Inc. ... solutions, today announced a strategic agreement with QualCare, Inc., a ... New Jersey regional marketplace.  This agreement will ... health and wellness solutions QualCare brings to its clients ... surrounding region. QualCare plans cover more ...
(Date:12/17/2014)... December 17, 2014 , ... than a hub of information concerning the biopharmaceutical Group,s national ... A further addition to the recently launched institutional website that ... now been enriched by a new chapter in the fascinating ... A richly detailed and panoramic hub on the world of ...
Breaking Medicine Technology:Separation Membranes Market (Company, Country & Application) Research Reports for Global and Chinese Regions 2Separation Membranes Market (Company, Country & Application) Research Reports for Global and Chinese Regions 3Strategic Health Services to collaborate with QualCare on Population Health and Wellness Technology for QualCare Members 2Strategic Health Services to collaborate with QualCare on Population Health and Wellness Technology for QualCare Members 3Dompé Offers a New "Window" on the World of Scientific Research, with the http://www.dompetrials.com Website, Dedicated to Clinical Trials 2Dompé Offers a New "Window" on the World of Scientific Research, with the http://www.dompetrials.com Website, Dedicated to Clinical Trials 3
... NEW YORK, April 27, 2011 ... biopharmaceutical company leveraging its proprietary drug-delivery platforms to develop treatments ... year,s Oncology Nursing Society (ONS) Congress at the Boston Convention ... booth (#652) will be displayed in the Exhibition Hall ...
... Medical Industries, Inc. (OTC: PDMI.PK) announced its success at ... which was held at the Houston Convention Center in ... practice optometrists from many of the most highly regarded ... the annual meeting.  The meeting provided opportunities for participating ...
Cached Medicine Technology:Access Pharmaceuticals to Attend the 36th Annual Oncology Nursing Society Congress 2Access Pharmaceuticals to Attend the 36th Annual Oncology Nursing Society Congress 3Paradigm is Successful at Annual Vision Source Meeting in Houston, Texas 2
(Date:12/20/2014)... Today, Balfleet.com, one of the most outstanding dressmakers ... off on its Mother of the Bride Dresses ... the bride dresses from Balfleet.com feature gorgeous looks and ... takes pride in providing high quality dresses to its ... discounts on our mother of the bride dresses, and ...
(Date:12/19/2014)... (PRWEB) December 20, 2014 Sweetdressy.com ... market, has introduced its newest selection of cheap prom ... are very popular in the world and clients can ... , Meanwhile, these prom dresses feature cool cuts and ... $200 now, targeting the middle-end market. Discount shipping costs ...
(Date:12/19/2014)... CA (PRWEB) December 19, 2014 ... corporation dedicated to developing educational events, tools and ... Rouxbe Cooking School , the world’s leading ... the prescription every human being needs: Culinary Rx. ... plant-based cooking course, Culinary Rx, scheduled for debut ...
(Date:12/19/2014)... Eufaula, Oklahoma, located just 9 miles ... state’s largest lake with more than 600 miles of ... a little more than 3,000 residents, hosted its annual ... 6th of December. , Featuring Santa, Christmas lights and ... on Main Street. Narconon Arrowhead’s parade float participated ...
(Date:12/19/2014)... (PRWEB) December 20, 2014 The Medspa ... new injectable filler from respected cosmetic brand Juvéderm. Voluma ... naturally with age. The Medspa at Hendrick is pleased ... in skin care technology to its clients. , Voluma ... to be FDA-approved to treat the mid-face and cheek ...
Breaking Medicine News(10 mins):Health News:Balfleet.com is Offering 50%-70% Off of its Mother of the Bride Dresses 2Health News:Cheap Prom Dresses Online Now at Sweetdressy.com 2Health News:The Plantrician Project and the Rouxbe Cooking School Join Forces to Develop Culinary Rx – a Plant-Prescription Course 2Health News:The Plantrician Project and the Rouxbe Cooking School Join Forces to Develop Culinary Rx – a Plant-Prescription Course 3Health News:The Plantrician Project and the Rouxbe Cooking School Join Forces to Develop Culinary Rx – a Plant-Prescription Course 4Health News:Narconon Arrowhead Debuts Float at Checotah and Eufaula Christmas Parades 2Health News:Narconon Arrowhead Debuts Float at Checotah and Eufaula Christmas Parades 3Health News:Breakthrough New Injectable Dermal Filler Voluma XC Offered by The MedSpa at Hendrick 2
... ... a common technology infrastructure for Policy, Compliance, Risk, SOX, Internal Audits and IT ... ... -- MetricStream, Inc. (“MetricStream”), the market leader in the enterprise-wide Governance, Risk ...
... (NYSE Alternext: ULU), a specialty pharmaceutical company ... and oral care products, today announced it has entered into ... at a price per share of $0.14 pursuant to a ... of approximately $1.5 million. , Investors will also receive warrants ...
... Mass., Nov. 12 Cequent Pharmaceuticals, a pioneer in ... to prevent and treat human disease, has announced that ... application with the U.S. Food and Drug Administration (FDA). ... candidate, targets beta-catenin, a key oncogene implicated in the ...
... Nov. 12 Mary Elizabeth Derig, of Seattle, Washington, ... Edition for her outstanding contributions and achievements in the ... ) , ABOUT MARY ELIZABETH ... an extensive career as a Registered Nurse including work ...
... (NYSE: ABT ) announced today a definitive agreement to ... antibody to Nerve Growth Factor (NGF), expanding the company,s pain ... a novel biologic in Phase I clinical trial development that ... released at sites of tissue damage and inflammation, and plays ...
... ... Mary Alexander will present during Class Action/Mass Torts session discussing tainted food products , ... San Francisco, CA (PRWEB) November 12, ... product law firms in the nation, will take the podium during the 48th Annual Consumer ...
Cached Medicine News:Health News:Amedisys Selects MetricStream for Integrated Enterprise-wide GRC 2Health News:ULURU Inc. to Raise $1.5 Million in Registered Direct Offering 2Health News:Cequent Files its First IND with FDA: CEQ508, a tkRNAi Drug Candidate in Oncology 2Health News:Cequent Files its First IND with FDA: CEQ508, a tkRNAi Drug Candidate in Oncology 3Health News:Cequent Files its First IND with FDA: CEQ508, a tkRNAi Drug Candidate in Oncology 4Health News:Mary Elizabeth Derig Recognized by Strathmore's Who's Who Worldwide Publication 2Health News:Abbott to Acquire Novel Investigational Biologic to Treat Chronic Pain 2Health News:California Consumer Attorney Mary Alexander to Present at 48th Annual COAC Convention 2
... C-terminal cleavage product produced during processing of ... molecule. Although the C-peptide of insulin is ... or extra-renal metabolism and therefore has a ... In addition, C-peptide assays may be analytically ...
... C-peptide of insulin is the C-terminal cleavage ... prohormone to the mature insulin molecule. Although ... it does undergo significant liver or extra-renal ... circulating half-life than insulin [1]. In addition, ...
... 1-2% of circulating testosterone exists as unbound ... is bound to SHBG with high affinity ... to albumin. Both the albumin-bound and free ... effectively inhibits testosterone action. Measurement of the ...
... the first, easy-to-use, non-invasive diagnostic technology ... cardiac dysfunction including acute heart failure, ... cardiac conditions. Designed to seamlessly fit ... enable clinicians caring for cardiac patients ...
Medicine Products: